Add Yahoo as a preferred source to see more of our stories on Google. With the rising demand for weight-loss medications, compounding pharmacies have been making headlines lately. On October 30, the ...

An estimated 5 million people are using compounded GLP-1s in the U.S., according to a Gallup poll released in July; of the 11 ...

A compounding pharmacy can prepare customized medications to fit your needs—but there are some things to be aware of. Rachel Fairbank is a freelance science writer based in Texas. When she is not ...

BERKELEY, Calif.--(BUSINESS WIRE)--Valor Compounding Pharmacy offers low-dose naltrexone, ketamine, and other alternative treatment options for the growing mental health crisis in the United States.

The More Life Company (MLCO.CN) entered into a non-binding letter of intent (LOI) with a US 503A compounding pharmacy to advance the development, compounding and commercialization of its Quicksome ...

A child who cannot swallow a pill. A patient allergic to an ingredient in a standard prescription. A medication that manufacturers have stopped making altogether. These are the kinds of challenges ...

A strategic letter of intent with an established U.S. 503A compounding pharmacy gives The More Life Company (CSE: MLCO, OTC: ...

BERKELEY, Calif.--(BUSINESS WIRE)--Valor Compounding Pharmacy is featured in Inc. 5000 this month discussing low-dose Naltrexone, Ketamine, and other treatment options as alternative medicine during ...

News of a recent meningitis outbreak has sent many Americans into panic mode. As of Thursday afternoon, 170 people in 11 states had become sick with the noncontagious fungal meningitis; 14 of those ...

Pharmacy compounding, the mixing of drugs for individual patients, was once a quaint activity depicted on drug-store calendars from the 1950s. It has roared back in the 21st century, driven by the ...

Dublin, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The "U.S. Compounding Pharmacy Market - Industry Outlook & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering. The U.S.

The FDA took issue with the volume of GLP-1 drugs that Empower produces, suggesting in the warning letter that the changes do not serve legitimate medical needs.